Sodium phenylbutyrate

Sodium phenylbutyrate (4-phenylbutyric acid, sodium salt; 4-PBA) is an aromatic short-chain fatty acid approved by the United States Food and Drug Administration since 1996 (Buphenyl) as adjunctive therapy in the chronic management of urea cycle disorders involving deficiencies of carbamyl phosphate synthetase, ornithine transcarbamylase, or argininosuccinate synthetase. The compound functions as a prodrug: hepatic and renal beta-oxidation converts phenylbutyrate to phenylacetate, which conjugates enzymatically with glutamine via hepatic and renal N-acyltransferases to form phenylacetylglutamine, a water-soluble conjugate excreted by the kidneys that carries two nitrogen atoms per molecule and thereby provides an alternative nitrogen disposal pathway independent of the defective urea cycle. Each gram of sodium phenylbutyrate administered generates approximately 0.12 to 0.15 grams of waste nitrogen as phenylacetylglutamine, an amount equivalent to the nitrogen content of urea. The compound is administered orally at 450 to 600 mg/kg in patients weighing less than 20 kilograms, or 9.9 to 13.0 g/m2 in larger patients, divided into three to six doses in the published literature with meals, to a maximum of 20 grams in the published literature.

Beyond the registered nitrogen-scavenging indication, sodium phenylbutyrate has attracted sustained research interest through two additional pharmacological mechanisms. First, the compound and its metabolite phenylacetate are pan-histone deacetylase (HDAC) inhibitors, active against Class I (HDAC1, 2, 3, 8), Class IIa (HDAC4, 5, 7, 9), and Class IIb (HDAC6, 10) isoforms at millimolar concentrations achievable with high-dose oral administration. HDAC inhibition produces chromatin remodeling, re-expression of silenced tumor suppressor genes, cell cycle arrest, differentiation, and apoptosis in malignant cells, effects that have been investigated in Phase 1 and Phase 2 clinical trials in recurrent malignant glioma, acute myeloid leukemia, solid tumors, and myelodysplastic syndrome. Second, 4-phenylbutyric acid functions as a low-molecular-weight chemical chaperone that stabilizes protein conformation, reduces endoplasmic reticulum stress, suppresses the unfolded protein response, and facilitates trafficking of misfolded proteins from the endoplasmic reticulum to the cell surface. This chemical chaperone mechanism has generated preclinical and early clinical evidence in cystic fibrosis (partial restoration of deltaF508-CFTR chloride channel trafficking to the apical membrane), spinal muscular atrophy (upregulation of SMN2 full-length transcript expression), Alzheimer disease (reduction of tau phosphorylation and neuroprotection in Tg2576 and other transgenic mouse models), Huntington disease (amelioration of polyglutamine-mediated neurodegeneration in N171-82Q mice), and amyotrophic lateral sclerosis. The compound was a component of the combination product AMX0035 (sodium phenylbutyrate plus taurursodiol, marketed as Relyvrio), which received accelerated FDA approval for ALS in September 2022 on the basis of the Phase 2 CENTAUR trial but was voluntarily withdrawn from the market in October 2024 after the confirmatory Phase 3 PHOENIX trial failed to meet its primary endpoint. Additional investigational applications include fetal hemoglobin induction in beta-thalassemia and sickle cell disease, and branched-chain amino acid reduction in maple syrup urine disease.

Pharmacokinetics are characterized by rapid oral absorption (Tmax approximately 1 hour), extensive first-pass hepatic beta-oxidation to phenylacetate (Tmax approximately 3.5 hours), short elimination half-lives for both parent compound (approximately 0.77 hours) and active metabolite (approximately 1.15 hours), and near-complete renal excretion of the glutamine conjugate (80 to 100 percent within 24 hours). The compound is well tolerated at registered doses for the urea cycle indication but carries a substantial pill burden (up to 40 tablets in the published literature at maximum dose) and produces characteristic adverse effects including menstrual dysfunction, metabolic acidosis, hypoalbuminemia, dysgeusia, body odor attributable to the phenylacetate metabolite, and dose-limiting neurotoxicity (somnolence, fatigue, disorientation) at the higher doses studied in oncology trials. Reformulation efforts including taste-masked granules (Pheburane) and the triglyceride prodrug glycerol phenylbutyrate (Ravicti, FDA-approved 2013) have addressed palatability and sodium load limitations. This monograph reviews the chemistry, synthesis, and structural class of sodium phenylbutyrate; the triple-mechanism pharmacology (nitrogen scavenging, HDAC inhibition, chemical chaperone activity); comprehensive pharmacokinetics; the clinical evidence base across urea cycle, oncology, neurodegenerative, hemoglobinopathy, and protein-misfolding indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five alternative nitrogen-scavenging or HDAC-modulating agents against sodium phenylbutyrate on five competency standards.